arrow
K

Kenneth Marek

institute for neurodegenerative disorders
H指数:78
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

作者更正:时间-事件分析缓解了症状性治疗对帕金森病试验中治疗效果的影响。

2025-08-130
OA
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
2025-03-010
OAAI
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease
2024-12-240
OAAI
Accelerating Parkinson's Disease drug development with federated learning approaches
2024-11-210
OAAI
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial
2024-10-080
OAAI
Multi-ancestry genome-wide association meta-analysis of Parkinson's disease

帕金森病多血统全基因组关联meta分析

2023-12-2822
OAAI
Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project
2023-12-223
OA
Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project
2023-10-0513
OAAI
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression
2023-07-1222
OAAI
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
2023-04-254
OAAI